Cytokinetics: Clinical Efficacy Isn’t Enough For Success (NASDAQ:CYTK)

David and Goliath on the house wall ,Regensburg,unesco heritage

kaetana_istock/iStock via Getty Images

At a Glance

In my previous analysis, I recommended a “Sell” position on Cytokinetics (NASDAQ:CYTK), a sentiment I largely maintain. The company faces heightened scrutiny with a declining revenue base, which fell from $89M to a

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *